Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Mar;11(2):171-82.
doi: 10.1586/erm.10.120.

Integrating Biomarkers in Clinical Trials

Affiliations
Review

Integrating Biomarkers in Clinical Trials

Marc Buyse et al. Expert Rev Mol Diagn. .

Abstract

Biomarkers have a growing role in clinical trials. With the advent of the targeted therapy era, molecular biomarkers in particular are becoming increasingly important within both clinical research and clinical practice. This article focuses on biomarkers that anticipate the prognosis of individual patients ('prognostic' biomarkers) and on biomarkers that predict how individual patients will respond to specific treatments ('predictive' biomarkers, also called 'effect modifiers'). Specific Phase II and III clinical trial designs are discussed in detail for their ability to validate the biomarker and/or to establish the effect of an experimental therapy in patient populations defined by the presence or absence of the biomarker. Contemporary biomarker-based clinical trials in oncology are used as examples.

Similar articles

See all similar articles

Cited by 29 articles

See all "Cited by" articles

LinkOut - more resources

Feedback